Results 131 to 140 of about 11,406 (228)
Epigenetic Alterations Beyond CpG Islands in Periodontitis: In Silico Study of DNA Methylation Data
ABSTRACT Objectives To classify differentially methylated CpG sites in periodontitis based on methylation shift direction and location relative to CpG islands. Material and Methods We integrated DNA methylation data from 65 gingival samples (31 periodontitis, 34 healthy) from three GEO datasets.
Koki Yoshida +2 more
wiley +1 more source
Personalised medicine of Cystic fibrosis [PDF]
Treballs Finals de Grau de Farmàcia, Facultat de Farmàcia, Universitat de Barcelona, 2017. Tutor: Carlos Julián Ciudad i Gómez[en] The European commission defines personalised medicine as a medical approach that uses molecular insights into health and ...
Cabré Juan, Antoni
core
ABSTRACT Background Cystic fibrosis (CF) monitoring relies on computed tomography (CT), but ultra‐short echo time MRI (UTE‐MRI) offers a radiation‐free alternative. However, its clinical adoption is hindered by the laborious and subjective manual analysis, which prevents standardized quantification of bronchial abnormalities.
Amel Imene Hadj Bouzid +11 more
wiley +1 more source
ABSTRACT Objective This study aimed to evaluate 5‐year outcomes of a structured quality improvement (QI) program implemented as part of the standard of care at our CF center, focusing on changes in body mass index (BMI) and forced expiratory volume in 1 s (FEV₁) in pwCF followed at our institution.
S. Karabulut +14 more
wiley +1 more source
Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]
Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada +2 more
core
Clinical pharmacology of CFTR modulators
With the development of cystic fibrosis transmembrane receptor (CFTR) modulating drugs, the landscape in cystic fibrosis (CF) care has changed dramatically. These drugs enable the treatment of the underlying cause of the disease. Although CFTR modulators show an impressive clincal effect at group level in people with CF (pwCF) with specific mutations ...
openaire +2 more sources
The combination of pharmacological modulators such as lumacaftor, tezacaftor, and elexacaftor restore CFTR activity at the plasma membrane and improve lung function in patients carrying CFTR mutations such as F508del, their effects on inflammation are ...
Amal Kouadri +20 more
doaj +1 more source
Chaperones as integrators of cellular networks: Changes of cellular integrity in stress and diseases
Cellular networks undergo rearrangements during stress and diseases. In un-stressed state the yeast protein-protein interaction network (interactome) is highly compact, and the centrally organized modules have a large overlap.
Albanese +54 more
core +2 more sources
Novel CFTR Modulators for Treating Cystic Fibrosis [PDF]
openaire +3 more sources
Cystic Fibrosis: Treatment with CFTR Modulators
CFTR modulators have been a groundbreaking new invention starting with the approval of the CFTR corrector Ivacaftor in 2012. Nowadays, up to 90% of CF patients have the potential ability to get treated by an appropriate CFTR modulator. Ivacaftor showed significant improvement in the treatment of CF patients with gating mutations, especially in G551D ...
openaire +2 more sources

